119 related articles for article (PubMed ID: 23042529)
41. The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologies.
Guo Y; You K; Geng L; Qiao J
J Gynecol Oncol; 2014 Oct; 25(4):287-92. PubMed ID: 25142625
[TBL] [Abstract][Full Text] [Related]
42. Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India.
Anand KV; Pimple SA; Bhattacharjee A; Mishra GA; Shastri SS
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2709-2716. PubMed ID: 34452578
[TBL] [Abstract][Full Text] [Related]
43. Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China.
Xu XQ; Rezhake R; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Ma JF; Qiao YL; Zhao FH; Cruickshank M
Cancer Prev Res (Phila); 2021 Mar; 14(3):363-372. PubMed ID: 33303694
[TBL] [Abstract][Full Text] [Related]
44. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
45. Comparative Assessment of a Self-sampling Device and Gynecologist Sampling for Cytology and HPV DNA Detection in a Rural and Low Resource Setting: Malaysian Experience.
Latiff LA; Ibrahim Z; Pei CP; Rahman SA; Akhtari-Zavare M
Asian Pac J Cancer Prev; 2015; 16(18):8495-501. PubMed ID: 26745108
[TBL] [Abstract][Full Text] [Related]
46. The clinical research of Thinprep Cytology Test (TCT) combined with HPV-DNA detection in screening cervical cancer.
Liu Y; Zhang L; Zhao G; Che L; Zhang H; Fang J
Cell Mol Biol (Noisy-le-grand); 2017 Feb; 63(2):92-95. PubMed ID: 28364788
[TBL] [Abstract][Full Text] [Related]
47. [New guidelines in regard to cervical cancer screening].
Vargas-Hernández VM; Acosta-Altamirano G; Moreno-Eutimio MA; Vargas-Aguilar VM
Cir Cir; 2014; 82(4):453-9. PubMed ID: 25167359
[TBL] [Abstract][Full Text] [Related]
48. Vaginal Self-Sampling for Human Papillomavirus Infection as a Primary Cervical Cancer Screening Tool in a Haitian Population.
Boggan JC; Walmer DK; Henderson G; Chakhtoura N; McCarthy SH; Beauvais HJ; Smith JS
Sex Transm Dis; 2015 Nov; 42(11):655-9. PubMed ID: 26462192
[TBL] [Abstract][Full Text] [Related]
49. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
50. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
51. ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients.
Husaiyin S; Jiao Z; Yimamu K; Maisaidi R; Han L; Niyazi M
PLoS One; 2021; 16(12):e0260915. PubMed ID: 34855928
[TBL] [Abstract][Full Text] [Related]
52. [Evaluation of variable methods for HPV testing].
Cheng JY; Bian ML; Ma L; Cong X; Chen Y; Liu J
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):589-94. PubMed ID: 24199924
[TBL] [Abstract][Full Text] [Related]
53. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
54. Screening of cervical neoplasia in HIV-infected women in India.
Joshi S; Sankaranarayanan R; Muwonge R; Kulkarni V; Somanathan T; Divate U
AIDS; 2013 Feb; 27(4):607-15. PubMed ID: 23079814
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology.
Bansal M; Zhao C
J Low Genit Tract Dis; 2011 Apr; 15(2):105-9. PubMed ID: 21317806
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the performance of paired urine and cervical samples for cervical cancer screening in screening population.
Xu H; Yu Y; George W; Smith JS; Hu S; Dang L; Zhang X; Pan Q; Qiao Y; Zhao F
J Med Virol; 2020 Feb; 92(2):234-240. PubMed ID: 31535725
[TBL] [Abstract][Full Text] [Related]
57. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
58. Primary HPV screening for cervical cancer.
Bhatla N; Singhal S
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():98-108. PubMed ID: 32291178
[TBL] [Abstract][Full Text] [Related]
59. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
Tranberg M; Jensen JS; Bech BH; Andersen B
BMC Infect Dis; 2020 Dec; 20(1):926. PubMed ID: 33276740
[TBL] [Abstract][Full Text] [Related]
60. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
